|
Technology Workshop Sponsors
|
 |
Immunogenicity Testing and Protein Engineering
Antitope is pioneering a new generation of immunogenicity testing, antibody humanization and protein engineering technologies. Our mission is to apply these technologies to create improved non-immunogenic biologics. Formed in 2004, Antitope offer proprietary technologies as a comprehensive service for evaluating immunogenicity, identifying T cell epitopes, producing fully human antibodies and generating non-immunogenic proteins. |
 |
Attana: Balancing Power and Simplicity in Molecular Interaction Studies. Attana is a pioneer in the development of affordable systems enabling real-time, label-free studies of molecular interactions. The A100® C-Fast system provides kinetics, off-rate screening and antibody selection, without the need of labels, resulting in faster and more cost-effective research. |
 |
BioWa is a subsidiary of Kyowa Hakko Kogyo Co., Ltd. of Japan, and is the exclusive licensor of AccretaMab™ platform. AccretaMab™ consists of POTELLIGENT® and COMPLEGENT™ technologies, creating a superior antibody molecule with enhanced ADCC and CDC. BioWa is offering these technologies to partners as well as developing ADCC/CDC-enhanced antibody therapeutics by itself. |
 |
Chiome Bioscience founded in 2005 is a well-funded biotech company addressing unmet medical needs by generating antibodies against difficult antigens. Chiome's fully proprietary platform technology—the ADLib® System—minimizes royalty stacking and provides unparalleled speed for novel antibody generation and adaptability to recalcitrant targets. |
 |
Codon Devices, Inc. is a biotechnology company focused on enabling commercial applications of synthetic biology. The company uses proprietary design and construction methods to rapidly engineer biological components for improved function. These methods reduce the risk and time associated with bioproduct development, creating significant value for our partners in the biotechnology, pharmaceutical, and agriculture sectors. |
 |
ForteBio commercializes a novel, label-free technology platform that includes instrument hardware, data acquisition and analysis software and biosensor chemistries to measure biomolecular interactions in real time. Its Octet® platform uses BioLayer Interferometry(BLI) to measure affinity, kinetics or concentration in crude or purified samples. "Dip and read" biosensors allow real time measurements directly in a 96 well microplate format without the use of any microfluidic channels, enabling the Octet platforms analytical capabilities to provide greater value in applications where existing methods such as surface plasmon resonance(SPR), ELISA and HPLC have limitations in throughput, performance, and cost. Visit www.fortebio.com for more information. |
 |
GENEART is the world market leader for DNA synthesis and a specialist in synthetic biology. Based on its gene design and DNA synthesis technology, GENEART supports the development of improved drugs and biotech products. The service portfolio ranges from gene optimization and synthetic gene production, gene variants and custom DNA libraries to plasmid preparations and DNA-based agents. |
 |
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. |
 |
MorphoSys AG, located in Martinsried/Munich, Germany, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. The Company, founded in 1992, possesses the unique HuCAL technology (the Human Combinatorial Antibody Library). This library comprises more than ten billion different, fully human antibodies. |
 |
The PERCIVIA PER.C6® Development Center develops the PER.C6® human cell line for recombinant proteins. PERCIVIA offers an integrated technology platform for protein production. The PERC.6® cell line generation technology offers cell culture development, up and downstream processes, design, scale-up, technology transfer, and regulatory support. |
 |
Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform and is a leader in the field of antibody Fc engineering to significantly improve antibody potency and half-life. The company is advancing XmAb® antibody drug candidates optimized for activity against biologically validated targets and its XPro™ protein therapeutic candidate into the clinic. Xencor's product development is led by an antibody candidate, XmAb®2513, in a Phase I clinical trial for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, and a protein therapeutic drug candidate, XPro™1595 DN-TNF, for the treatment of inflammatory disease. With multiple partners, such as industry leaders Genentech, Boehringer Ingelheim, Centocor, MedImmune and Human Genome Sciences, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. For more information, please visit www.xencor.com.
|
 |
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies and has a fully integrated infrastructure including preclinical through manufacturing. XOMA leverages a broad technology platform of six commercial antibody phage display libraries, custom human antibody phage display libraries, hybridoma, Human Engineering™ and affinity maturation technologies. |
|
